Plus Therapeutics Management
Management criteria checks 2/4
Plus Therapeutics' CEO is Marc Hedrick, appointed in May 2004, has a tenure of 21.58 years. total yearly compensation is $1.13M, comprised of 49.1% salary and 50.9% bonuses, including company stock and options. directly owns 0.004% of the company’s shares, worth $306.34. The average tenure of the management team and the board of directors is 4.4 years and 3.8 years respectively.
Key information
Marc Hedrick
Chief executive officer
US$1.1m
Total compensation
| CEO salary percentage | 49.1% |
| CEO tenure | 20yrs |
| CEO ownership | 0.004% |
| Management average tenure | 4.4yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
Plus Therapeutics jumps 18% as JonesTrading adds another Buy rating
Oct 07Plus Therapeutics finalizes $17.6M grant from Texas, to get initial funds by October end
Sep 22Plus Therapeutics GAAP EPS of -$0.24 misses by $0.02
Jul 21Plus Therapeutics CEO Dr. Marc Hedrick - Cancer's Hardest Problems
Dec 21Does Plus Therapeutics (NASDAQ:PSTV) Have A Healthy Balance Sheet?
Aug 25
Plus Therapeutics to proceed with eighth cohort in ReSPECT glioblastoma trial
Jun 16Shareholders May Not Be So Generous With Plus Therapeutics, Inc.'s (NASDAQ:PSTV) CEO Compensation And Here's Why
May 11Plus Therapeutics shares rise 5% on Rhenium NanoLiposome development contract
May 04Is Plus Therapeutics (NASDAQ:PSTV) Using Debt Sensibly?
Feb 23Plus Therapeutics shows positive data for ReSPECT Phase 1 clinical trial in GBM
Nov 19CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$1m | US$556k | -US$13m |
| Sep 30 2023 | n/a | n/a | -US$15m |
| Jun 30 2023 | n/a | n/a | -US$17m |
| Mar 31 2023 | n/a | n/a | -US$21m |
| Dec 31 2022 | US$955k | US$535k | -US$20m |
| Sep 30 2022 | n/a | n/a | -US$19m |
| Jun 30 2022 | n/a | n/a | -US$17m |
| Mar 31 2022 | n/a | n/a | -US$15m |
| Dec 31 2021 | US$2m | US$510k | -US$13m |
| Sep 30 2021 | n/a | n/a | -US$13m |
| Jun 30 2021 | n/a | n/a | -US$11m |
| Mar 31 2021 | n/a | n/a | -US$10m |
| Dec 31 2020 | US$1m | US$510k | -US$8m |
| Sep 30 2020 | n/a | n/a | -US$4m |
| Jun 30 2020 | n/a | n/a | -US$2m |
| Mar 31 2020 | n/a | n/a | -US$2m |
| Dec 31 2019 | US$867k | US$510k | -US$4m |
| Sep 30 2019 | n/a | n/a | -US$7m |
| Jun 30 2019 | n/a | n/a | -US$11m |
| Mar 31 2019 | n/a | n/a | -US$9m |
| Dec 31 2018 | US$615k | US$510k | -US$11m |
| Sep 30 2018 | n/a | n/a | -US$18m |
| Jun 30 2018 | n/a | n/a | -US$19m |
| Mar 31 2018 | n/a | n/a | -US$24m |
| Dec 31 2017 | US$846k | US$500k | -US$27m |
Compensation vs Market: Marc's total compensation ($USD1.13M) is above average for companies of similar size in the US market ($USD674.46K).
Compensation vs Earnings: Marc's compensation has increased whilst the company is unprofitable.
CEO
Marc Hedrick (60 yo)
20yrs
Tenure
US$1,134,027
Compensation
Dr. Marc H. Hedrick, M.D., M.B.A., serves as President of Plus Therapeutics, Inc. (also known as Cytori Therapeutics, Inc.) since May 2004 and has been its Chief Executive Officer since April 2, 2014. Dr....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 20yrs | US$1.13m | 0.0040% $ 306.3 | |
| VP of Finance & CFO | 4.3yrs | US$539.23k | 0.019% $ 1.5k | |
| Chief Medical Officer & Senior VP | 2.5yrs | US$675.27k | 0% $ 0 | |
| Corporate Controller | 4.5yrs | no data | no data | |
| Chief Scientist | no data | no data | no data |
4.4yrs
Average Tenure
60yo
Average Age
Experienced Management: PSTV's management team is considered experienced (4.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 21.6yrs | US$1.13m | 0.0040% $ 306.3 | |
| Independent Director | 4.1yrs | US$52.87k | 0.59% $ 45.3k | |
| Independent Director | 4.3yrs | US$80.37k | 0.57% $ 43.5k | |
| Independent Chairman of the Board | 16.4yrs | US$102.87k | 0.000020% $ 1.5 | |
| Independent Director | 4.1yrs | US$75.37k | 0.27% $ 21.0k | |
| Member of Scientific Advisory Board | 3.5yrs | no data | no data | |
| Member of Clinical Advisory Board | 3.6yrs | no data | no data | |
| Independent Director | 4.3yrs | US$65.37k | 0% $ 0 | |
| Member of Clinical Advisory Board | 3.6yrs | no data | no data | |
| Member of Clinical Advisory Board | 3.6yrs | no data | no data | |
| Member of Clinical Advisory Board | 3.6yrs | no data | no data | |
| Member of Clinical Advisory Board | 3.6yrs | no data | no data |
3.8yrs
Average Tenure
66yo
Average Age
Experienced Board: PSTV's board of directors are considered experienced (3.8 years average tenure).